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A deleterious RNF43 germline mutation in a severely affected
serrated polyposis kindred
Douglas Taupin1,2, Wesley Lam3, David Rangiah4, Larissa McCallum2, Belinda Whittle5, Yafei Zhang5, Daniel Andrews5,6,
Matthew Field5,6, Christopher C Goodnow5,6 and Matthew C Cook3,6
We report a germline nonsense mutation within the extracellular domain of the RING finger ubiquitin ligase RNF43, segregating
with a severe form of serrated polyposis within a kindred. The finding provides evidence that inherited RNF43 mutations define a
familial cancer syndrome.
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The serrated polyposis syndrome comprises multiple epithelial
polyps in the colon and rectum of serrated histology. WHO clinical
criteria1 are the presence of 420 serrated polyps throughout the
colon, or45 proximal to the rectum. Serrated polyps, particularly
large sessile polyps in the proximal colon, frequently exhibit the
oncogenic V600E mutation together with hypermethylation
of the mismatch repair protein MLH1 and are responsible for
15–20% of sporadic colorectal cancer (CRC).2
The serrated polyposis syndrome is associated with CRC risk.
Serrated polyposis shows familial clustering,3 and first and second-
degree relatives of index cases with serrated polyposis without
CRC are more likely to have been diagnosed with CRC or
pancreatic cancer.4 The risk of CRC in relatives is higher in those
cases diagnosed below the age of 50 years.4 A small number of
serrated polyposis patients harbor dominant germline mutations
in mismatch repair proteins or biallelic MUTYH mutations,
however, when these patients are excluded the familial risk of CRC
remains4 and the genetic basis for familial serrated polyposis has
not been established. The appearance of serrated polyposis in
consanguineous kindreds and in monozygotic twins5 has led to
the hypothesis that serrated polyposis may be due in part to
recessive or codominant mutations.5
As serrated polyposis is a relatively newly described condition,
its natural history is not known and the lifetime risk of CRC in
serrated polyposis is also not known. Significantly, it is also not
known whether those first and second-degree relatives of serrated
polyposis cases, who had a history of CRC or pancreatic cancer,
themselves had serrated polyposis.4 If so, then a dominant mode
of inheritance in at least a subset of serrated polyposis is likely.
If not, however, serrated polyposis could be the result of several
codominant alleles.
We identified a severely affected kindred with serrated
polyposis. The proband developed microsatellite instability
(MSI)– CRC age 23 years arising from a serrated polyp, in the
setting of multiple (450) large serrated polyps throughout the
colon; one sibling has multiple serrated polyps and another a
single large adenoma. Their mother developed pancreatic cancer
and died before this study at age 50 years. On the paternal side,
an informative pedigree had no history of multiple polyposis or
CRC in the father’s generation. Full sequencing of the MUTYH gene
in the proband did not reveal any abnormality.
We performed exon capture and deep sequencing in this
kindred to identify strong and potentially interacting cancer
alleles.
EXOME SEQUENCING
DNA library preparation and exome enrichment was performed at
the Australian Phenomics Facility, Australian National University.
Input DNA was extracted from saliva, analyzed for integrity then
fragmented by mechanical shearing (Covaris AFA). The Agilent
XT2 Human, all exon, V5.0 kit and referenced reagents (Agilent,
Santa Clara, CA, USA) were utilized for DNA library preparation and
exome enrichment. Libraries were indexed and pooled in batches
of six before capture. Enriched libraries were sequenced as paired
end reads (100 bp runs) on an Illumina HiSeq 2000 at the
Australian Cancer Research Foundation (ACRF) Biomolecular
Resource Facility at the John Curtin School of Medical Research,
Australian National University.
BIOINFORMATICS
Sequence reads were mapped to the GRCh37 assembly of the
reference human genome using the default parameters of the
Burrows–Wheeler Aligner.6 Untrimmed reads were aligned
allowing a maximum of two seed mismatches with repetitively
aligned reads discarded. Sequence variants were identified with
SAMtools7 and classified as novel, rare (mean allele frequency/
MAF⩽ 0.02), or common (MAF40.02). Variants were overlapped
to ENSEMBL v75 exons and splice site coordinates and annotated
using the Ensembl Variant Effect Predictor (VEP)8 to obtain
PolyPhen29 and SIFT10 scores for estimating the effect of amino
acid substitutions on protein structure and function. Deleterious
SNVs in cancer genes were assessed against the COSMIC database
and assigned a value. Variant analysis of sequenced pedigrees
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(pVAAST)11 was performed treating subject 002 as ‘unaffected’ or
‘affected’.
VALIDATION OF CANDIDATE DELETERIOUS MUTATIONS
Genotyping for the specific mutations in the probands and
relatives were performed by exon-specific PCR and Sanger
sequencing.
Subjects gave written informed consent for the study, which
received approval from the ACT Health Research Ethics
Committee.
RESULTS
The pedigree of the affected kindred is shown in Figure 1a. The
proband II.2, a male nonsmoker of 23, underwent emergency right
hemicolectomy for an obstructing CRC and multiple synchronous
polyps were palpated at operation. The primary tumor was staged
T4N0MX. Immunohistochemistry for the mismatch repair genes
was normal. The somatic KRAS codon 12 and 13 mutation panel
(COSMIC ID: 516, 517, 518, 520, 521, 522 and 532) was negative.
Sequencing of the MUTYH gene in the germline was normal.
A female sibling II.3, age 27 years, underwent screening
colonoscopy where 420 large serrated polyps were identified.
After endoscopic failure to achieve endoscopic clearance of polyps
the subject underwent elective subtotal colectomy; 460 polyps
were present in the resection specimen. A third sibling II.1, age 21
years, had a single adenoma of the rectum; a second colonoscopy
at 1 year was normal.
We performed whole-exome capture and sequencing (median
depth for four exomes was 99× ). Variant analysis of sequenced
pedigrees was performed treating subject II.1 as ‘unaffected’ or
‘affected’. Rare and novel variant analysis identified 49 variants
that conformed to an autosomal dominant inheritance pattern. Of
these, 9 were novel variants and 40 were rare (MAFo0.02), and
only one was a nonsense variant, which was a novel (R132X)
mutation in RNF43 (Figure 1b). This allele was found in subjects II.2
and II.3. Separately, 42 rare or novel variants were identified
irrespective of inheritance pattern. Of these, 20 nonsense
mutations were identified of which only the previously identified
missense RNF43 mutation was segregated with the serrated
polyposis phenotype in the pedigree. We confirmed the RNF43
nonsense mutation by Sanger sequencing (Figure 1c).
The mutant allele detected in subjects II.2 and II.3 was present
on the minus strand, chromosome 17q22 coordinates 56431037
to 56494931 and represent a C4T transversion at cDNA position
2350 within exon 2 (g.54014C4T). The residue is highly conserved
in mammals and birds (Figure 1d), and is located within a well-
conserved region that encodes the extracellular protein domain.
As a result of this premature stop codon, mutant mRNA is
predicted to undergo nonsense mediated decay.
RNF43 encodes a transmembrane RING finger ubiquitin ligase.
Amongst its substrates are Wnt agonist frizzled receptors, which
are targeted to the lysosome for degradation;12 a mutation in the
RING finger domain that inactivated E3 ligase activity increased
Wnt signaling.13
Complete Sanger sequencing of RNF43 in each extant member
of the pedigree revealed one additional coding variant
g.56656C4T in II.3. This missense substitution encodes P231L,
and is not predicted to be damaging. Twenty-three instances of
homozygosity for this variant have been reported in the TGP
database. No somatic mutations replicating this variant have been
reported in cancer samples.
We did not determine expression of either the mutant allele or
the paternal allele in neoplastic tissue in subjects II.2 or II.3. We
expect little or no expression of the mutant allele owing to
nonsense mediated decay. As a candidate tumor suppressor gene,
RNF43 may be subject to allelic loss or somatic inactivation of the
wild-type allele, which is a question for further scrutiny.
RNF43 germline mutations (encoding R113X) were amongst
several germ line mutations reported recently in 2 of 20 unrelated
sporadic serrated polyposis cases.14 Recently, Giannakis et al.15
described somatic mutations in RNF43 occurring in 18.9% of 185
CRC cases, 17.6% of an independent cohort of 222 CRC cases and
18.1% of 248 endometrial cancer. The majority of RNF43 somatic
mutations reported were truncating events (including three
instances of R132X), and were strongly associated with MSI-
positive cancers and negatively associated with APC mutations,
leading Giannakis et al. to propose that mismatch repair deficiency
leads to a permissive environment for the acquisition of RNF43
mutations. Taken together with the prior report of Gala et al., our
data indicate that RNF43 truncations may instead be pathogenic in
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Figure 1. (a) Pedigree with closed symbols, affected; open symbols, unaffected; gray symbol, deceased. (b) Summary of combined results from
whole exome capture and sequencing of genomic DNA from subjects I.2, II.1, II.2 and II.3. Mutations were deemed to be rare (MAFo0.02) or
novel in reference to dbSNP. The number of missense, splice site and nonsense single-nucleotide variants (SNV) are shown assuming II.2 and
II.3 are affected, and I.2 and II.1 are unaffected. (c) Sanger sequencing of genomic DNA from extant members of the kindred. (d) Conservation
of region encompassing arginine converted to stop codon by nonsense mutation. (e) Summary of RNF43 gene structure. Mutated residue is
indicated (red triangle) located within the extracellular domain.
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the serrated polyposis-cancer sequence, which is independent of
the canonical APC mutant adenomatous polyp and in which MSI,
when it occurs, arises owing to somatic methylation of the MLH1
gene.16 Furthermore, our report of evidence of heterozygous
RNF43 mutations segregating with serrated polyposis within a
kindred raises the possibility that this represents a new familial
cancer syndrome.
HGV DATABASE
The relevant data from this Data Report are hosted at the Human
Genome Variation Database at http://dx.doi.org/10.6084/m9.fig
share.hgv.582.
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